Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Trials & Filings in Brief: Nov. 22, 2013 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Trials & Filings in Brief: Nov. 22, 2013

Bayer, Biogen Idec, DelMar, Janssen, J&J, Pfizer, Regeneron, Sanofi, Threshold

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I
DelMar presents dose-escalation interim results . . . read more

No dose-limiting toxicity in Threshold study . . . read more

Phase III
Sanofi, Regeneron RA drug shows effectiveness . . . read more

Filings
Biogen idec drug gets protection in EU . . . read more

Eylea approved in Japan . . . read more

J&J diabetes treatment approved in EU . . . read more

Xalkori gets full approval . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics